WHO chief warns health gains at risk as funding falters

2 May 2025

The head of the World Health Organization (WHO) has issued a stark warning that sudden cuts to global health budgets, including by the USA, are putting years of medical progress in jeopardy.

The move, which follows foreign aid reductions by the Trump administration, has led to an increase in disease outbreaks, particularly in conflict-ridden areas. “We are living through the greatest disruption to global health financing in memory,” said WHO director-general Tedros Adhanom Ghebreyesus, speaking to reporters in Geneva.

He said the situation is already deteriorating in countries such as Angola, where cholera has infected more than 17,000 people and killed over 550 this year alone. The outbreak, the worst in two decades, has been exacerbated by poor access to clean water and sanitation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical